Phrixus Pharmaceuticals, Inc. Announces $890,000 in NIH Funding for Its Programs in Duchenne Muscular Dystrophy and Heart Failure

Phrixus Pharmaceuticals, Inc. Announces $890,000 in NIH Funding for Its Programs in Duchenne Muscular Dystrophy and Heart Failure: "Phrixus Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on innovative therapies for Duchenne muscular dystrophy (DMD) and heart failure, today announced that it has received a total of $890,000 in awards from the National Institutes of Health (NIH). Funding is in the form of one SBIR Phase 1 award titled 'Effects of P-188 on Respiratory Function and Diaphragm Degeneration in the mdx Mouse' and one STTR Phase 1 award titled 'Poloxamer 188 Mechanism of Action in Ischemic Heart Failure.' The latter award is in collaboration with Dr. Joseph M. Metzger, Chair of Integrative Biology and Physiology at the University of Minnesota."